[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital of Xi'an Jiaotong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":341},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,71,93,114,133,151,168,188,216,234,254,275,297,320],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652947","heated-humidified-oxygen-in-pacu-patients-100652947",false,"NCT07778420","Heated Humidified Oxygen in PACU Patients","Effect of Heated and Humidified Oxygen Therapy on the Incidence of Early Hypoxemia in Adult Patients During General Anesthesia Recovery in the Post-Anesthesia Care Unit: A Prospective, Multicenter, Randomized, Superiority Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Undergoing elective or emergency surgery under general anesthesia with endotracheal intubation\n3. Ramsay Sedation Score of 2-4 at 1 minute after extubation\n4. ASA physical status class I-III\n5. Expected PACU stay ≥ 30 minutes\n6. Patient or legally authorized representative provides written informed consent\n\nExclusion Criteria:\n\n1. Pre-existing hypoxemia (SpO₂ \\\u003C 90% on room air)\n2. Pre-existing diagnosis of severe chronic obstructive pulmonary disease (GOLD grade 3-4), interstitial lung disease, or uncontrolled asthma\n3. Severe cardiovascular disease (NYHA class III-IV heart failure, unstable angina)\n4. Neuromuscular disease affecting respiratory function\n5. Maxillofacial surgery, severe spinal deformity, or other contraindications to face mask oxygen therapy or positioning\n6. Use of cardiopulmonary bypass during surgery or planned postoperative ICU admission with endotracheal tube in place\n7. Known intolerance to heated gas","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to determine whether heated and humidified oxygen therapy, compared with conventional room-temperature oxygen therapy, reduces the incidence of early hypoxemia in adult patients recovering from general anesthesia in the Post-Anesthesia Care Unit (PACU).\n\nHypoxemia is a common and potentially life-threatening complication during PACU recovery, resulting from residual anesthetics, decreased upper airway muscle tone, atelectasis, and suppression of hypoxic pulmonary vasoconstriction (HPV). Heated and humidified oxygen may offer benefits by preserving optimal HPV function, protecting airway mucosa, and reducing respiratory resistance.\n\nThis is a prospective, multicenter, randomized, superiority trial with a parallel-group design. A total of 2,000 adult patients (ASA class I-III) undergoing general anesthesia will be enrolled and randomly assigned in a 1:1 ratio to receive either heated and humidified oxygen (37°C, 5 L\u002Fmin via face mask) or room-temperature oxygen (room temperature, 5 L\u002Fmin via face mask).\n\nThe primary outcome is the incidence of hypoxemia, defined as SpO₂ ≤ 90% lasting ≥ 5 seconds, within 10 minutes after initiation of the intervention. Secondary outcomes include severe hypoxemia (SpO₂ ≤ 85%), requirement for airway interventions, lowest SpO₂ value, PACU length of stay, postoperative shivering, and agitation. Safety outcomes include nasal discomfort, epistaxis, and device-related adverse events.",[26,27,28],"Hypoxemia","Postoperative Complications","Anesthesia Recovery Period",[30,31,32,33,34,35],"Heated and Humidified Oxygen","General Anesthesia","PACU","Randomized Controlled Trial","Oxygen Therapy","Post-Anesthesia Care Unit","NOT_YET_RECRUITING","2026-08-18",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":42,"type":20},"2026-09-01",{"date":44,"type":20},"2027-12-30",{"name":46,"class":47},"Second Affiliated Hospital of Xi'an Jiaotong University","OTHER",8,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100649375","phase-4-ebastine-for-adjuvant-treatment-of-tumor-budding-positive-liver-cancer-after-surgery-100649375","NCT07734766","Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery","A Single-Arm Study of Ebastine as Adjuvant Therapy in Patients With Tumor Budding-Positive Hepatocellular Carcinoma After Curative Hepatectomy","Inclusion Criteria:\n\n* Age is ≥18 years old, male or female;\n* Histologically confirmed as hepatocellular carcinoma without metastasis;\n* Tumor budding is positive\n* Life expectancy of at least 12 weeks;\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma that cannot be surgically resected\n* Received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. before surgery\n* Pregnant or lactating women\n* Subjects with other malignant tumors;\n* Subjects who are considered unsuitable to participate in this cohort study by the investigator;\n* Subjects who refuse to enroll or do not sign the informed consent form;\n* Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.).",{"count":57,"type":20},45,[59],"PHASE4","This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose tumors show a histopathological feature known as tumor budding, which is associated with a higher risk of postoperative recurrence.\n\nEbastine is a second-generation antihistamine approved for allergic conditions. Preclinical studies have shown that ebastine also inhibits FAK signaling, a pathway implicated in tumor invasion, epithelial-mesenchymal transition, and recurrence. This study investigates whether administering ebastine after surgery can lower the recurrence risk associated with tumor budding-positive HCC.\n\nAll enrolled participants will receive ebastine as adjuvant treatment following hepatectomy. The primary endpoint is the 1-year recurrence-free survival (RFS) rate. Secondary endpoints include 2-year RFS, overall survival, and safety.\n\nAll participants in this study will receive ebastine as adjuvant (after-surgery) treatment. Researchers will monitor whether the cancer stays away for at least one year after surgery (recurrence-free survival), as well as overall survival and any side effects.",[62],"Hepato Cellular Carcinoma","2026-07-24",{"date":65,"type":40},"2026-07-29",{"date":67,"type":20},"2026-10-01",{"date":69,"type":20},"2030-03-01",{"name":46,"class":47},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100648174","inter-individual-tumor-heterogeneity-on-3d-mre-for-predicting-response-to-conversion-therapy-in-liver-cancer-100648174","NCT07716345","Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer","A Prospective Study on Inter-Individual Tumor Heterogeneity Assessed by Three-Dimensional Magnetic Resonance Elastography for Predicting Response to Conversion Therapy in Patients With Liver Cancer","Inclusion Criteria:\n\n* Age 18-75 years\n* Pathologically or radiologically confirmed diagnosis of initially unresectable liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis)\n* Planned to receive conversion therapy with the intent of achieving surgical resectability\n* Child-Pugh class A or B liver function (for patients with primary liver cancer)\n* ECOG performance status 0-1\n* At least one measurable lesion per RECIST 1.1\n* Able to undergo 3D-MRE examination prior to conversion therapy\n* Provision of signed and dated informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Child-Pugh class C liver function (for patients with primary liver cancer)\n* Uncontrolled ascites, hepatic encephalopathy, or variceal bleeding within 3 months prior to enrollment\n* Other concurrent active malignancy\n* Severe comorbidities precluding conversion therapy or surgery\n* Pregnant or breastfeeding women\n* Anticipated poor compliance with repeated MRE examinations or follow-up","75 Years",{"count":80,"type":20},100,"OBSERVATIONAL","How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing. Substantial variation exists among patients in their tumor response to the same conversion therapy regimen, and current pretreatment imaging assessment does not adequately capture this inter-individual variability. We hypothesize that baseline tumor viscoelastic parameters measured by three-dimensional magnetic resonance elastography (3D-MRE) differ substantially across patients, and that this inter-individual heterogeneity may be associated with differential response to conversion therapy. This study aims to prospectively evaluate the association between baseline 3D-MRE-derived tumor viscoelastic parameters and pathological response as well as surgical conversion outcomes across patients with liver cancer receiving conversion therapy.",[62,84,85],"Intrahepatic Bile Duct Carcinoma","Metastatic Hepatocellular Carcinoma","2026-07-20",{"date":88,"type":40},"2026-07-21",{"date":67,"type":20},{"date":91,"type":20},"2030-10-01",{"name":46,"class":47},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100648013","wearable-sweat-sensor-for-high-concentration-lactate-monitoring-in-critically-ill-patients-100648013","NCT07716371","Wearable Sweat Sensor for High-Concentration Lactate Monitoring in Critically Ill Patients","Development and Preliminary Clinical Validation of a Wearable Sweat Sensor for High-Concentration Lactate Monitoring in Critically Ill Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Admitted to the surgical intensive care unit (ICU)\n* Blood lactate concentration \\> 1.5 mmol\u002FL\n* Age ≥ 16 years\n* Willing to voluntarily donate samples and provide signed informed consent\n\nExclusion Criteria:\n\n* Pregnant women\n* Pre-existing hematologic disease prior to infection\n* Long-term use of immunosuppressive agents or presence of immunodeficiency\n* Skin too dry to allow adequate sweat collection","16 Years",{"count":102,"type":20},86,"Blood lactate level is closely associated with the prognosis of patients with sepsis and septic shock. Clinical guidelines explicitly recommend blood lactate monitoring in septic patients and lactate-guided fluid resuscitation when lactate levels are elevated. Dynamic monitoring of serum lactate changes and calculation of lactate clearance can more accurately reflect the dynamic changes in tissue oxygen supply and consumption, and can be used to evaluate tissue perfusion and oxygen metabolism. However, most existing wearable sweat sensors have a detection range of only 0-20 mmol\u002FL, which is suitable only for monitoring during exercise under normal physiological conditions and cannot meet the clinical monitoring needs of patients with hyperlactatemia. In addition, current wearable sweat lactate sensors suffer from poor reproducibility and are easily affected by environmental factors and complex sweat composition, which represent major obstacles to clinical translation. Therefore, this project aims to develop a wearable sweat sensor for high-concentration lactate monitoring and to conduct preliminary clinical validation in critically ill patients, by simultaneously measuring blood and sweat lactate concentrations and establishing their correlation, with the goal of achieving non-invasive and convenient disease monitoring through sweat biomarker detection.",[105,106,107],"Sepsis","Severe Sepsis With Septic Shock","Severe Sepsis Without Septic Shock",{"date":88,"type":40},{"date":110,"type":20},"2026-08-01",{"date":112,"type":20},"2029-10-01",{"name":46,"class":47},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":132,"locationsCount":4},"100647989","wearable-patch-ultrasound-probe-for-diagnosis-of-liver-stiffness-100647989","NCT07716384","Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness","Diagnostic Accuracy of a Wearable Patch-Type Ultrasound Probe for Detecting Liver Fibrosis and Cirrhosis: A Prospective Cross-Sectional Study","Inclusion Criteria:\n\n* Confirmed or suspected chronic liver disease (including but not limited to chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease)\n* Scheduled to undergo, or have recently undergone, transient elastography (FibroScan) as part of routine clinical care\n* Age ≥ 18 years\n* Willing and able to provide signed informed consent\n\nExclusion Criteria:\n\n* Ascites (may interfere with liver stiffness measurement by either device) Body mass index (BMI) ≥ 35 kg\u002Fm² (may reduce measurement reliability of transient elastography)\n* Acute hepatitis or acute-on-chronic liver failure at the time of enrollment\n* History of liver transplantation\n* Hepatocellular carcinoma or other space-occupying liver lesions\n* Pregnant women\n* Skin lesions, infection, or scarring at the intended probe application site (right lobe of the liver, intercostal space)\n* Unable to cooperate with the measurement procedure (e.g., severe cognitive impairment)",{"count":122,"type":20},150,"Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease. Transient elastography (FibroScan) is currently the most widely used non-invasive reference standard, but it requires a dedicated device and trained operator, which may limit its accessibility in some clinical settings. This study aims to evaluate the diagnostic accuracy of a novel wearable patch-type ultrasound probe for detecting significant liver fibrosis and cirrhosis, using FibroScan as the reference standard. Patients with chronic liver disease will undergo simultaneous liver stiffness measurement using both the wearable patch ultrasound probe and FibroScan. The diagnostic performance of the patch probe, including sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), will be evaluated against fibrosis staging determined by FibroScan, along with the correlation and agreement between the two measurement methods.",[125,126,127,128],"Liver Fibrosis","Liver Cirrhosis","NAFLD (Nonalcoholic Fatty Liver Disease)","HEPATITIS B CHRONIC",{"date":88,"type":40},{"date":67,"type":20},{"date":91,"type":20},{"name":46,"class":47},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100647270","peritumoral-mre-stiffness-for-predicting-resection-margin-status-and-recurrence-in-liver-cancer-100647270","NCT07704216","Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer","A Prospective Study on the Association Between Peritumoral Elasticity Measured by Three-Dimensional Magnetic Resonance Elastography and Pathological Resection Margin Status and Postoperative Recurrence in Patients With Liver Cancer","Inclusion Criteria:\n\n* Age 18-80 years\n* Pathologically confirmed diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis (e.g., from colorectal cancer)\n* Underwent curative-intent hepatectomy with available postoperative pathological resection margin assessment\n* Child-Pugh class A or B liver function (for patients with primary liver cancer)\n* Able to undergo 3D-MRE examination at postoperative day 7-14\n* Provision of signed and dated informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobia)\n* Palliative or non-curative surgery (R2 resection)\n* Presence of unresectable extrahepatic disease at the time of surgery\n* Reoperation or unplanned return to surgery within 14 days after the initial hepatectomy\n* Severe postoperative complications precluding MRI examination at postoperative day 7-14 (e.g., unstable vital signs, need for intensive care)\n* Death within 14 days after surgery from non-tumor-related causes\n* Prior history of liver resection or liver transplantation\n* Pregnant or breastfeeding women\n* Anticipated poor compliance with postoperative MRE examination or follow-up","80 Years",{"count":122,"type":20},"Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the resected specimen, which reflects only the removed tissue rather than the actual remnant liver in the patient. How to non-invasively detect residual tumor at the resection margin of the remnant liver after surgery remains an important unresolved problem in the surgical management of liver cancer. We hypothesize that tissue stiffness at the resection margin of the remnant liver, measured by postoperative three-dimensional magnetic resonance elastography (3D-MRE), may reflect microscopic residual tumor and may therefore correlate with pathological resection margin status and be predictive of postoperative tumor recurrence. This study aims to prospectively evaluate the diagnostic performance of postoperative 3D-MRE in detecting residual tumor at the resection margin, using pathological resection margin status as the reference standard, and to further assess its value in predicting tumor recurrence in patients undergoing hepatectomy for liver cancer.",[62,84,85],"2026-07-10",{"date":146,"type":40},"2026-07-15",{"date":110,"type":20},{"date":149,"type":20},"2031-10-01",{"name":46,"class":47},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":158,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":167,"locationsCount":4},"100647213","preoperative-3d-magnetic-resonance-elastography-for-predicting-surgical-risk-in-patients-undergoing-hepatectomy-100647213","NCT07704203","Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy","A Prospective Study on Preoperative Regional Liver Function Assessment Using Three-Dimensional Magnetic Resonance Elastography for Predicting Surgical Risk and Postoperative Liver Failure in Patients Undergoing Hepatectomy for Primary or Metastatic Liver Cancer","Inclusion Criteria:\n\n* Age 18-80 years\n* Pathologically or radiologically confirmed diagnosis of one of the following: hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis (e.g., from colorectal cancer)\n* Scheduled to undergo curative hepatectomy\n* Child-Pugh class A or B liver function\n* Able to tolerate MRI examination\n* Provision of signed and dated informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobia)\n* Child-Pugh class C liver function\n* Prior history of liver resection or liver transplantation\n* Presence of extrahepatic metastasis\n* Emergency surgery (e.g., due to tumor rupture)\n* Severe cardiopulmonary or renal dysfunction precluding surgery\n* Pregnant or breastfeeding women\n* Unwillingness or inability to comply with study procedures or follow-up",{"count":122,"type":20},"How to accurately and safely evaluate regional liver function before hepatectomy remains an important unsolved problem in the surgical management of hepatocellular carcinoma (HCC). We plan to develop a non-invasive, functional 3D-MRE-based method for preoperative regional hepatic functional reserve assessment, and to evaluate its ability to predict surgical risk and postoperative liver failure in patients with HCC undergoing hepatectomy.",[161,162,163,85],"Hepatic Cancer","Hepatocellular Carcinoma","Intrahepatic Cholangiocellular Carcinoma",{"date":146,"type":40},{"date":110,"type":20},{"date":91,"type":20},{"name":46,"class":47},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100605272","phase-4-exploration-of-postoperative-adjuvant-therapy-for-hcc-patients-with-positive-tb-100605272","NCT07160361","Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB","Exploration of Postoperative Adjuvant Therapy for Hepatocellular Carcinoma Patients With Positive Tumor Budding",{"count":175,"type":20},56,[59],"Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer worldwide, characterized by complex and variable disease progression and significant treatment challenges. Among HCC patients, tumor budding (TB) is associated with a high risk of postoperative recurrence, significantly impacting patient prognosis. Even in the current HCC pathological diagnosis \"gold standard\" of MVI-negative patients, TB retains excellent prognostic predictive value. TB cells reside within the peritumoral stroma, where dense collagen fibers restrict the efficacy of therapeutic agents including chemotherapy, immunotherapy, and targeted therapies, making it difficult for single-agent treatments to effectively eliminate TB. Therefore, specific treatment strategies should be considered for TB-positive patients to improve survival outcomes and reduce the risk of tumor recurrence. To address this clinical challenge, this study aims to clarify the prognostic impact of combining collagen degradation therapy with targeted therapy in TB-positive HCC patients. Through a single-arm trial (postoperative targeted therapy + collagen degradation therapy), investigators explore the clinical efficacy and prognostic indicators of this combination approach, seeking the optimal treatment strategy for TB-positive HCC patients. Collagen degradation therapy facilitates drug delivery to tumor-bottle lesions by degrading collagen barriers, while targeted therapy specifically intervenes against cancer cells. Their combination holds promise for synergistic effects and enhanced therapeutic outcomes. This study aims to preliminarily assess the impact of this dual approach on prognosis, providing evidence for personalized treatment strategies. The findings of this research hold promise for delivering new breakthroughs in the treatment of TB-positive HCC patients, improving their quality of life and survival rates, and providing robust support for future clinical practice.",[179],"Carcinoma, Hepatocellular","2025-09-10",{"date":182,"type":40},"2025-09-16",{"date":184,"type":20},"2025-10-01",{"date":186,"type":20},"2029-12-31",{"name":46,"class":47},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":140,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},"100576877","phase-3-a-clinical-study-on-the-benefits-of-carbon-nanoparticles-injection-time-in-patients-with-thyroid-cancer-100576877","NCT06791005","A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.","A Comparative Study of Preoperative and Intraoperative Carbon Nanoparticles Injection in Patients Undergoing Thyroid Cancer Surgery","Inclusion Criteria:\n\n* Preoperative pathological assessment indicated the presence of thyroid cancer with a maximum diameter of less than 4 cm.\n* Postoperative pathological evaluation confirmed bilateral thyroid cancer or lateral lymph node metastasis.\n* Vocal cord examination conducted one week prior to surgery revealed no abnormalities.\n* The patient had no history of prior thyroid surgery and required a total thyroidectomy.\n* Blood pressure was stably controlled.\n* The patient regained consciousness and was able to communicate normally.\n\nExclusion Criteria:\n\n* Prior to enrollment, the patient had received radiotherapy, chemotherapy, or isotope therapy.\n* A documented history of thyroid surgery.\n* Age under 16 years.\n* Known allergies to the medications under investigation or an inability to tolerate surgical intervention.\n* Presence of a retrosternal thyroid tumor.\n* Tumor invasion of the parathyroid glands and\u002For the recurrent laryngeal nerve during surgical procedures.\n* Postoperative pathology suggestive of medullary carcinoma or undifferentiated carcinoma.\n* Development of a postoperative tracheal fistula.",{"count":196,"type":20},400,[198],"PHASE3","The detection rate of thyroid cancer (PTC) has increased rapidly in recent years. Except undifferentiated cancer, surgery is still one of the most important treatments for all types of thyroid cancer, and there is a consensus to use the lobes of the gland as the minimum extent of resection. In the meantime, a basic consensus has been reached that central zone lymph node (VI) dissection is the minimum extent of lymph node dissection. In clinical practice, neck surgery and lumpectomy are mostly performed. Hypoparathyroidism and recurrent laryngeal nerve injury are the most common complications of radical surgery for thyroid cancer, both in open surgery and the luminal approach. Once these complications occur, they have a serious impact on the quality of life of patients in the postoperative period. A number of contrast agents are now being used to help minimize complications. Carbon nanoparticles are an effective and non-harmful negative developer, and many studies have confirmed that carbon nanoparticles can be used to identify parathyroid glands in thyroid surgery. Intraoperative injection of nanocarbon is effective in increasing the quality of intraoperative parathyroid detection and lymph node clearance and reducing adverse effects, such as postoperative hypokalemia.However, there is no complete clinical guideline for preoperative intraglandular injection of carbon nanoparticles, and there is no standardized dosage for appropriate injection time, injection dose, and injection method. At the same time, there is still the problem of carbon nanoparticle leakage. At our medical center, we have found that preoperative injection of carbon nanoparticles via ultrasound-guided fine needle puncture may yield better results by reducing CNS exudation in the surgical area. In this study, we will collect more than 400 patients who underwent thyroidectomy in 2025 and underwent carbon nanoparticle injections at different time points and analyzed their intraoperative and postoperative conditions as a basis for analyzing the difference in patient benefits between preoperative and intraoperative carbon nanoparticle injections and to provide data to support the clinical use of carbon nanoparticles.",[201],"Papillary Thyroid Cancer",[201,203,204,205],"thyroid surgery","developer","complication","RECRUITING","2025-01-18",{"date":209,"type":40},"2025-01-24",{"date":211,"type":40},"2025-01-01",{"date":213,"type":20},"2025-09-30",{"name":46,"class":47},1,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100574271","a-study-on-the-efficacy-of-immunotherapy-the-occurrence-and-severity-of-adverse-reactions-in-patients-with-non-small-cell-lung-cancer-in-high-altitude-areas-100574271","NCT06757114","A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas","A Study on the Multi-omic Factors Influencing the Efficacy of Immunotherapy and Adverse Reactions of Immunotherapy in Patients with Primary Non-small Cell Lung Cancer in High-altitude Areas","Inclusion Criteria:\n\n* (1) Patients with primary non-small cell lung cancer (adenocarcinoma\u002Fsquamous cell carcinoma\u002Fadenosquamous cell carcinoma\u002Flarge cell lung cancer\u002Fothers) with clear cellular\u002Fhistopathological evidence; (2) Primary non-small cell lung cancer of any stage receiving immunotherapy for the first time; (3) Patients who have undergone at least 2 cycles of immunotherapy during the treatment period and have undergone one efficacy evaluation; (4) Patients with at least one evaluable target lesion (except for those with uncontrolled brain metastases) according to Response Evaluation Criteria for Solid T Tumors (RECIST, version 1.1); (5) Voluntary participation in research and strong willingness to cooperate; (6) has been residing in Qinghai Province since birth; (7) Have been residing in Shaanxi Province since birth; (8) Be at least 18 years old;\n\nExclusion Criteria:\n\n1. Patients with unknown histopathological type were excluded;\n2. Patients with unclear diagnosis and treatment information and immunotherapy-related adverse reactions;\n3. Patients with bipolar\u002Fmultiple primary non-small cell lung cancer with other tumors were excluded;\n4. Patients who are unwilling to join the study and have poor willingness to cooperate;\n5. Patients who migrated to Qinghai or Shaanxi from different altitudes and had a history of migration between the two provinces were excluded;\n6. exclude patients with a history of emigration from parents;\n7. Patients who have received immunotherapy for other tumors in the past;\n8. Prior immunosuppressive therapy prior to exclusion",{"count":224,"type":20},200,"As a major disease with high incidence and mortality rate, lung cancer seriously threatens the health of our people and causes a huge burden of disease. In recent years, with the widespread use of immune checkpoint inhibitors (ICIs), great progress has been made in the treatment of lung cancer, which has brought significant survival benefits to patients. Although ICI has greatly improved the prognosis of lung cancer patients, due to the complexity of the mechanism of action of ICI and the heterogeneity within the tumor, the benefit population of treatment is relatively limited, and some patients are still at risk of primary drug resistance and tumor hyperprogression.In this study, we aimed to compare the differences in the efficacy and adverse reactions of immunotherapy in patients with advanced non-small cell lung cancer at high and low altitudes, and to find out the relevant factors from multiple omics such as imaging, pathology, and genetics, so as to solve the problem of immunotherapy resistance",[227],"Non-small Cell Lung Cancer(NSCLC)",{"date":229,"type":40},"2025-01-03",{"date":211,"type":20},{"date":232,"type":20},"2025-06-30",{"name":46,"class":47},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":241,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":242,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":215},"100553696","fecal-amino-acidsgut-taste-receptors-and-irritable-bowel-syndromes-100553696","NCT06489444","Fecal Amino Acids，Gut Taste Receptors and Irritable Bowel Syndromes","Alterations in Nutrient-sensing Mechanisms May Play a Role in Symptom Generation in Patients With IBS","Inclusion Criteria:\n\n* Patients with IBS who meet the Rome IV diagnostic criteria:\n\n  1. that is, recurrent abdominal pain, with symptoms occurring at least 1 day per week or at least 3 days per month on average in the last 3 months, combining 2 or more of the following:\n\n     1. related to defecation;\n     2. accompanied by changes in the frequency of bowel movements;\n     3. Accompanied by changes in fecal characteristics (appearance). (Symptoms appeared at least 6 months before diagnosis, and above diagnostic criteria were met in the last 3 months) 2. Age ≥18 years old.\n\nExclusion Criteria:\n\n* 1\\. History of celiac disease and other organic intestinal diseases, metabolic diseases (thyroid dysfunction, diabetes, etc.); (2) Serious neurological, mental and psychological diseases, or accompanied by serious organ dysfunction; 3. Abdominal surgery; 4. Pregnant, possible pregnant and lactating patients; 5. History of colonoscopy in the past 1 year; 6. Declined to participate in the study.",true,{"count":80,"type":20},"Clinical data, fresh feces and intestinal mucosal tissues of patients with diarrheal IBS were collected. High performance liquid chromatography, immunohistochemistry and immunofluorescence were used to study the amino acid levels in feces of patients with IBS, the expression of taste receptors in intestinal mucosa, and the correlation between symptoms of abdominal pain and diarrhea and the expression of taste receptors, so as to obtain the conclusion that \"intestinal amino acid perception abnormalities exist in patients with IBS. And correlated with clinical symptoms.\"",[245],"Irritable Bowel Syndrome","2024-07-02",{"date":248,"type":40},"2024-07-08",{"date":250,"type":40},"2023-03-16",{"date":252,"type":20},"2024-08",{"name":46,"class":47},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":215},"100552100","improvements-in-thyroid-tumor-surgery-and-the-prognosis-diagnosis-recurrence-and-metastasis-of-patients-100552100","NCT06468696","Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients","Inclusion Criteria:\n\n1. Perform transthoracic endoscopic thyroidectomy via breast approach;\n2. Postoperative pathology confirms benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or cervical CT suggests no extrathyroidal invasion or distant metastasis of the tumor;\n4. No contraindications for general anesthesia;\n5. Patients with cosmetic requirements.\n\nExclusion Criteria:\n\n1. Underwent transthoracic endoscopic thyroidectomy;\n2. Postoperative pathology confirmed as benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or neck CT suggested no extraglandular invasion or distant metastasis of the tumor;\n4. No contraindications to general anesthesia;\n5. Patients with cosmetic demands.",{"count":261,"type":20},170,[23],"The objective of this research is to investigate the clinical outcomes of modified surgical techniques such as omitting the cervical linea alba suture in transthoracic endoscopic thyroidectomy. Furthermore, the study requires the collection of normal thyroid tissues, benign and malignant thyroid tumors, and lymph nodes to further clarify the mechanisms associated with the initiation, progression, metastasis, and recurrence of thyroid cancer.",[201,265,266],"Lymph Node Metastasis","Carcinogenesis","2024-06-20",{"date":269,"type":40},"2024-06-21",{"date":271,"type":40},"2023-04-01",{"date":273,"type":20},"2026-01-01",{"name":46,"class":47},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100541983","phase-2-adibelimab-famitinib-and-chemotherapy-for-advanced-nsclc-after-pd-1-inhibitor-failure-100541983","NCT06336954","Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure","Exploratory Study of Adibelimab Combined With Famitinib and Chemotherapy for the Treatment of Patients With Driver Gene-Negative Locally Advanced or Metastatic NSCLC Progressing After PD-1 Monoclonal Antibody Combined With Chemotherapy","Inclusion Criteria:\n\n* Participants must be adults (≥18 years) who have signed an informed consent form.\n* They should have an ECOG performance status of 0-1. Diagnosed with stage IIIB-IV NSCLC and have progressed after PD-1 inhibitor treatment.\n* Expected to live at least 3 months and have at least one measurable lesion per RECIST v1.1.\n* Laboratory test results must meet specific criteria for blood counts, liver and kidney function, and coagulation parameters.\n* Patients with stable, treated brain metastases are eligible.\n* Women of childbearing potential and men with partners of childbearing potential must agree to use contraception.\n\nExclusion Criteria:\n\n* Prior therapy with anti-PD-L1, anti-PD-L2, other immune checkpoint inhibitors, or specific cancer treatments.\n* Certain cancer types, known mutations, or recent use of systemic corticosteroids or immunosuppressive medications.\n* Active brain or leptomeningeal metastases without stability post-treatment, recent severe infections, or major surgery.\n* Other conditions that might interfere with the study, such as uncontrollable third-space fluid accumulations, active autoimmune diseases or infections, significant bleeding or thromboembolic events, serious heart conditions, severe allergies to study drugs, other active malignancies, HIV\u002FAIDS, hepatitis B or C infection, or participation in another interventional clinical study within a specified period.",{"count":283,"type":20},40,[285],"PHASE2","This prospective, single-arm trial explores the efficacy of Adibelimab monoclonal antibody combined with Famitinib and chemotherapy in treating locally advanced or metastatic NSCLC patients with negative driver genes who have progressed after PD-1 monoclonal antibody and chemotherapy treatment. The study focuses on assessing progression-free survival (PFS) in 40 participants. Key objectives include evaluating PFS and understanding the progression patterns post-first-line immunotherapy, with an interest in whether switching from PD-1 to PD-L1 inhibitors can overcome immune resistance.",[288],"Non Small Cell Lung Cancer","2024-03-27",{"date":291,"type":40},"2024-03-29",{"date":293,"type":20},"2024-03-30",{"date":295,"type":20},"2026-12-31",{"name":46,"class":47},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":140,"enrollmentInfo":304,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":215},"100538115","prediction-of-lymph-node-metastasis-in-patients-with-thyroid-malignancy-by-a-new-scale-100538115","NCT06286631","Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale","Quantitative Rating Scale Based on Preoperative Prediction of Lymph Node Dissection in Patients With Thyroid Cancer","Inclusion Criteria:\n\n* Papillary thyroid cancer\n* Conscious and able to communicate normally\n* Age 16-80 years\n\nExclusion Criteria:\n\n* Preoperative or postoperative pathology suggests other types of tumors, such as medullary carcinoma or undifferentiated carcinoma.\n* Less than 16 years of age",{"count":305,"type":20},800,"The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis. Lymph node involvement in PTC patients is usually related to the recurrence of PTC after surgery, and 30% of patients recur without lymph node dissection, with the risk of central cervical lymph node metastasis being the greatest, so it seems to be a good choice to perform lymph node dissection on patients after thyroidectomy, but in fact, there are controversies at home and abroad as to whether to perform lymph node dissection or not. The 2021 Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of differentiated thyroid cancer state that prophylactic central lymph node dissection (PCND) may increase the incidence of postoperative complications, but due to the high metastatic rate of PTC and the ability of PCND to effectively prevent recurrence and reoperation, countries in the East Asian region perform prophylactic lymph node dissection on almost all patients with PTC. However, for more countries in Europe and the United States, performing PCND has become a non-essential, individualized option. The aim of this study is to collect multifactorial data from more than 1,000 patients who have undergone previous thyroidectomy from 2021 to 2023, and to develop a novel scoring scale that can be used to individualize patients' scores based on a variety of factors prior to surgery, so that patients can be more accurately predicted to have lymph node metastasis and need prophylactic lymph node dissection prior to surgery, and patients who do not need dissection can avoid surgery. For patients who do not need lymph node dissection, complications caused by surgery can be avoided, while for patients who do have lymph node metastasis, recurrence of their cancer can be prevented. This will change the status quo of not being able to accurately determine the actual situation through simple preoperative examination or performing prophylactic lymph node dissection for all PTC patients.",[201],[201,309,310,311,312],"pre-operative","Prophylactic lymph node dissection","lymphatic node transfer","Multi-factor data","2024-02-22",{"date":315,"type":40},"2024-02-29",{"date":317,"type":40},"2023-05-01",{"date":67,"type":20},{"name":46,"class":47},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":241,"sex":16,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":215},"100461674","screening-for-early-gastric-cancer-in-shaanxi-province-100461674","NCT05291728","Screening for Early Gastric Cancer in Shaanxi Province","Inclusion Criteria:\n\n* Local resident over 20 years old.\n* Obtain verbal informed consent of the subject.\n\nExclusion Criteria:\n\n* Refused to participate in this research project.\n* Questionnaires or serological tests for helicobacter pylori antibodies were not completed.\n* This study was not completed due to other reasons.","20 Years",{"count":328,"type":20},12500000,"This study collect the relevant data of local residents over 20 years old in 11 regions of Shaanxi Province, The basic information of the subjects was collected by filling in the questionnaire, and serum helicobacter pylori antibody detection was completed at the same time. The expert group determined the high-risk population of gastric cancer after comprehensive evaluation. All the high-risk population of gastric cancer without contraindications underwent electronic gastroscopy in the designated hospital after signing the informed consent. By collecting and analyzing data, early gastric cancer screening was completed and a new gastric cancer risk assessment model was established to evaluate the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as helicobacter pylori infection, radical treatment and recurrence rate.",[331],"Early Gastric Cancer",[333],"early GC,Hp infection,FD, GERD , precancerous lesions","2022-03-13",{"date":336,"type":40},"2022-03-23",{"date":338,"type":40},"2020-10-01",{"date":67,"type":20},{"name":46,"class":47},""]